Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence.

IF 6.9 1区 医学 Q1 IMMUNOLOGY NPJ Vaccines Pub Date : 2024-08-07 DOI:10.1038/s41541-024-00915-y
Bärbel Friedrichs, Simone Rehg, Kay-Martin Hanschmann, Volker Öppling, Isabelle Bekeredjian-Ding
{"title":"Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence.","authors":"Bärbel Friedrichs, Simone Rehg, Kay-Martin Hanschmann, Volker Öppling, Isabelle Bekeredjian-Ding","doi":"10.1038/s41541-024-00915-y","DOIUrl":null,"url":null,"abstract":"<p><p>Lot release testing of diphtheria, tetanus and acellular pertussis vaccines traditionally relied on in vivo protection models involving challenge of laboratory animals with toxins. Meanwhile, many labs have switched to serological testing of these vaccines, which is often performed in separate in vivo assays, even if all components were formulated into one vaccine product. Here we describe the results of simultaneous serological potency determination of diphtheria (D), tetanus (T) and acellular pertussis (aP) antigens obtained following immunization of guinea pigs with multicomponent pediatric and booster vaccines from different manufacturers. The 4th World Health Organization (WHO) International Standard (IS) for diphtheria toxoid (No. 07/216) and the 4th WHO IS for tetanus toxoid (No. 08/218) were used as reference preparations. For aP, a pediatric vaccine batch containing the antigens pertussis toxoid, filamentous hemagglutinin, pertactin and fimbriae proteins type 2/3 was established as internal control. Quantification of IgG against D, T and aP antigens in guinea pig sera was performed using a hexaplex electrochemiluminescence immunoassay. We further provide proof-of-concept using experimental vaccine samples lacking or containing reduced amounts of diphtheria toxoid in the presence of full amounts of tetanus and pertussis antigens and alum adjuvant. Importantly, the assay confirmed dose-response relationships for all antigens tested and was able to detect diphtheria out-of-specification batches. The results confirmed the suitability of the protocol for combined serology batch release testing of DTaP combination vaccines as first measure towards implementation of full in vitro testing of DTaP vaccines. This report summarizes the data and the protocol used for validation prior to implementation of this method in routine batch release testing of DTaP vaccines, which led to replacement of in vivo challenge experiments in our laboratory following the 3 R (replace, reduce, refine) principle.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"142"},"PeriodicalIF":6.9000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306252/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00915-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Lot release testing of diphtheria, tetanus and acellular pertussis vaccines traditionally relied on in vivo protection models involving challenge of laboratory animals with toxins. Meanwhile, many labs have switched to serological testing of these vaccines, which is often performed in separate in vivo assays, even if all components were formulated into one vaccine product. Here we describe the results of simultaneous serological potency determination of diphtheria (D), tetanus (T) and acellular pertussis (aP) antigens obtained following immunization of guinea pigs with multicomponent pediatric and booster vaccines from different manufacturers. The 4th World Health Organization (WHO) International Standard (IS) for diphtheria toxoid (No. 07/216) and the 4th WHO IS for tetanus toxoid (No. 08/218) were used as reference preparations. For aP, a pediatric vaccine batch containing the antigens pertussis toxoid, filamentous hemagglutinin, pertactin and fimbriae proteins type 2/3 was established as internal control. Quantification of IgG against D, T and aP antigens in guinea pig sera was performed using a hexaplex electrochemiluminescence immunoassay. We further provide proof-of-concept using experimental vaccine samples lacking or containing reduced amounts of diphtheria toxoid in the presence of full amounts of tetanus and pertussis antigens and alum adjuvant. Importantly, the assay confirmed dose-response relationships for all antigens tested and was able to detect diphtheria out-of-specification batches. The results confirmed the suitability of the protocol for combined serology batch release testing of DTaP combination vaccines as first measure towards implementation of full in vitro testing of DTaP vaccines. This report summarizes the data and the protocol used for validation prior to implementation of this method in routine batch release testing of DTaP vaccines, which led to replacement of in vivo challenge experiments in our laboratory following the 3 R (replace, reduce, refine) principle.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用电化学发光法进行多重免疫原性测试,确定百白破疫苗的效力。
白喉、破伤风和无细胞百日咳疫苗的批签发测试传统上依赖于体内保护模型,包括用毒素挑战实验动物。与此同时,许多实验室已转而对这些疫苗进行血清学检测,而血清学检测通常是在单独的体内试验中进行的,即使所有成分都已配制成一种疫苗产品。在此,我们介绍了不同生产商生产的多组分儿科疫苗和加强免疫疫苗免疫豚鼠后,对白喉(D)、破伤风(T)和无细胞百日咳(aP)抗原同时进行血清学效价测定的结果。白喉类毒素的第四版世界卫生组织国际标准(IS)(编号 07/216)和破伤风类毒素的第四版世界卫生组织国际标准(IS)(编号 08/218)被用作参考制剂。对于 aP,则以含有百日咳类毒素、丝状血凝素、百日咳素和 2/3 型缘膜蛋白质抗原的儿科疫苗批次作为内部对照。豚鼠血清中针对 D、T 和 aP 抗原的 IgG 定量是通过六联电化学发光免疫测定法进行的。我们使用缺乏或含有少量白喉类毒素的实验疫苗样品,在存在全量破伤风和百日咳抗原及明矾佐剂的情况下,进一步证明了这一概念。重要的是,该检测方法证实了所有测试抗原的剂量反应关系,并能检测出白喉超标批次。结果证实了该方案适用于白喉、破伤风和百日咳联合疫苗的联合血清学批次释放测试,是实施白喉、破伤风和百日咳联合疫苗全面体外测试的第一步。本报告总结了在 DTaP 疫苗常规批签发测试中实施该方法之前用于验证的数据和方案,这导致我们实验室按照 3R(替换、减少、改进)原则替换了体内挑战实验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NPJ Vaccines
NPJ Vaccines Immunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍: Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.
期刊最新文献
The PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia. Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity. MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates. Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine. Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1